Illumina Upgrades Custom Genotyping Offering to Suit Human Health, Ag-bio Market Needs

Tristan Orpin, Illumina's chief commercial officer, said this week that the added flexibility of the iSelect custom genotyping offering will allow the firm to reach more customers doing human health and ag-bio research.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories